Search

Your search keyword '"Wajja A"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Wajja A" Remove constraint Author: "Wajja A" Database Unpaywall Remove constraint Database: Unpaywall
37 results on '"Wajja A"'

Search Results

1. Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial

2. Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control

3. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

4. Establishing a Single-Sex Controlled Human Schistosoma mansoni Infection Model for Uganda: Protocol for Safety and Dose-Finding Trial

5. The Effect of Bcg Revaccination on the Response to Unrelated Vaccines in Urban Ugandan Adolescents: Results of the Popvac C Randomised, Controlled Trial

6. Does Schistosome or Malaria Exposure Contribute to Urban-Rural Differences in Vaccine Responses in Uganda? A Causal Mediation Analysis Using Data from Three Linked Randomised Controlled Trials

7. The Effect of Intensive Praziquantel Treatment on Vaccine-Specific Responses Among Schoolchildren in Ugandan Schistosomiasis-Endemic Islands: Results of the Popvac a Randomised, Controlled Trial

8. The Effect of Intermittent Preventive Treatment for Malaria with Dihydroartemisinin-Piperaquine on Vaccine-Specific Responses Among Schoolchildren in Rural Uganda: Results of the POPVAC B Randomised, Controlled Trial

9. Knowledge, Attitudes, and Practices Regarding COVID-19 among Healthcare Workers in Uganda: A Cross-Sectional Survey

10. Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda

11. Analysis of the MUII-plus mentorship programme: reflections of Fellows’ experiences and lessons for other programmes

12. Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics

13. Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the ‘POPulation differences in VACcine responses’ (POPVAC) programme

14. Analysis of the MUII-plus mentorship programme: reflections of Fellows’ experiences and lessons for other programmes

15. Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda

16. Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda

17. Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A

18. Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders’ meeting held in Entebbe, Uganda.

19. Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders’ meeting held in Entebbe, Uganda.

20. The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial

23. Distinct T-Cell Responses When BCG Vaccination Is Delayed From Birth to 6 Weeks of Age in Ugandan Infants

25. Species and genotypic diversity of non-tuberculous mycobacteria isolated from children investigated for pulmonary tuberculosis in rural Uganda

26. An Early Morning Sputum Sample Is Necessary for the Diagnosis of Pulmonary Tuberculosis, Even with More Sensitive Techniques: A Prospective Cohort Study among Adolescent TB-Suspects in Uganda

33. Activation of β‐Chemokines and CCR5 in Persons Infected with Human Immunodeficiency Virus Type 1 and Tuberculosis

34. Macrophage‐Activating Cytokines in Human Immununodeficiency Virus Type 1–Infected and –Uninfected Patients with Pulmonary Tuberculosis

Catalog

Books, media, physical & digital resources